| 19.09 14:45 | dpa-AFX: Incyte To Present At Cantor Global Healthcare Conference; Webcast At 9:45 AM ET |
| 19.09 03:00 | dpa-AFX: Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal |
| 06.09 15:46 | dpa-AFX: Incyte To Present At Morgan Stanley Global Healthcare Conference; Webcast At 10:45 AM ET |
| 18.08 07:44 | dpa-AFX: Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out |
| 30.07 13:29 | dpa-AFX: *INCYTE Q2 TOTAL REVENUES $1.044 BLN, UP 9% Y/Y |
| 30.07 13:21 | dpa-AFX: Incyte Corporation Q2 Earnings Summary |
| 30.07 13:07 | dpa-AFX: *INCYTE Q2 GAAP LOSS PER SHARE $2.04; NON-GAAP LOSS PER SHARE $1.82 |
| 30.07 10:19 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 29.07 10:15 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 13.05 16:54 | dpa-AFX: Incyte Gains 8% On Share Buy Back Authorization Of Up To $2.0 Bln |
| 13.05 16:29 | dpa-AFX: *INCYTE TO BUY BACK UP TO $2.0 BLN OF ITS COMMON STOCK |
| 30.04 13:22 | dpa-AFX: Incyte Corporation Q1 Profit Increases, but misses estimates |
| 30.04 13:11 | dpa-AFX: *INCYTE Q1 GAAP EPS $0.75; NON-GAAP EPS $0.64 |
| 30.04 13:00 | dpa-AFX: Incyte Q1 24 Earnings Conference Call At 8:00 AM ET |
| 23.04 14:14 | dpa-AFX: Incyte To Buy Privately Held Escient Pharma |
| 23.04 13:40 | dpa-AFX: *INCYTE TO ACQUIRE ESCIENT AND ITS ASSETS FOR $750 MLN PLUS ESCIENT'S NET CASH REMAINING |
| 01.04 15:10 | dpa-AFX: CMS To Receive License To Develop, Commercialize Povorcitinib In China And Southeast Asia |
| 01.04 14:59 | dpa-AFX: *CMS, INCYTE ANNOUNCE COLLABORATION AND LICENSE DEAL FOR POVORCITINIB IN CHINA AND SOUTHEAST ASIA |
| 28.02 03:25 | dpa-AFX: Incyte's Axatilimab Receives FDA Priority Review For Chronic Graft-Versus-Host Disease Treatment |
| 13.02 13:35 | dpa-AFX: Incyte Q4 Adj EPS Misses Estimates, But Revenues Top |
|
|
